Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,380 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- OncoTree
- PROSTATE
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,984 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00668642 | Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer | completed | Phase 2 | 20 | Endeavor HealthOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT01331083 | A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer | completed | Phase 2 | 68 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 22, 2023 | clinicaltrials |
| NCT00002889 | Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer | completed | Phase 2 | 180 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05489991 | A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | terminated | Phase 1 / Phase 2 | 1 | Tceleron Therapeutics, Inc.INDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT00786682 | Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 2 | 11 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT04066894 | Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05900973 | A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer | unknown | Phase 2 | 19 | D'Or Institute for Research and EducationOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT00093457 | Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer | completed | Phase 2 | 28 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00258388 | Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy | completed | Phase 2 | 82 | NCIC Clinical Trials GroupNETWORK | 2 | Aug 4, 2023 | clinicaltrials |
| NCT01075308 | SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer | completed | Phase 2 | 32 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT01619813 | Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer | completed | Phase 2 | 85 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04936334 | The Role of 68Ga-PSMA-11 PET (Prostate Specific Membrane Antigen) in Surgery Guidance in Prostate Cancer | completed | Phase 2 | 51 | Clinton BahlerOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT01666808 | FACBC Outcomes for Post Prostatectomy | completed | Phase 2 / Phase 3 | 165 | Emory UniversityOTHER | 1 | Aug 2, 2023 | clinicaltrials |
| NCT02499835 | Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 66 | University of Wisconsin, MadisonOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT03658447 | PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)(PRINCE) | completed | Phase 1 / Phase 2 | 37 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Jul 28, 2023 | clinicaltrials |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 4 | Jul 25, 2023 | clinicaltrials |
| NCT05955209 | Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC) | unknown | Phase 2 | 40 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jul 21, 2023 | clinicaltrials |
| NCT02326805 | PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance | completed | Phase 2 | 154 | National Cancer Institute (NCI)NIH | 1 | Jul 19, 2023 | clinicaltrials |
| NCT03456804 | ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 2 | 13 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT04781374 | Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05549778 | Polaprezinc Treatment for Enzalutamide- or Abiraterone-resistant CRPC(PEACe) | completed | Phase 1 / Phase 2 | 12 | Jiangnan UniversityOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT03735680 | A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer | completed | Phase 2 | 30 | OncoNano Medicine, Inc.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT02640534 | Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone | terminated | Phase 2 | 169 | Swiss Cancer InstituteOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT04654338 | 2 Ablative RadioTherapy Treatments for Prostate Cancer(EARTH) | recruiting | Phase 2 / Phase 3 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT04995978 | Insulin Resistance and Androgen Deprivation Therapy | withdrawn | Phase 2 | 0 | St. Louis UniversityOTHER | 1 | Jun 23, 2023 | clinicaltrials |
| NCT00003871 | PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer | completed | Phase 2 | 60 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT00005847 | Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT01326312 | Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer(GTx758) | terminated | Phase 2 | 159 | GTxINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT00003614 | Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 15, 2023 | clinicaltrials |
| NCT04676607 | SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 2 | 6 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT02952534 | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency(TRITON2) | completed | Phase 2 | 277 | pharmaand GmbHINDUSTRY | 12 | Jun 9, 2023 | clinicaltrials |
| NCT02516670 | Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 2 | 50 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 7, 2023 | clinicaltrials |
| NCT00866554 | Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy | completed | Phase 2 | 60 | CHU de Quebec-Universite LavalOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT00771017 | Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer | withdrawn | Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 0 | May 25, 2023 | clinicaltrials |
| NCT00987753 | Study Evaluating the Safety and Tolerability of L-377202 | completed | Phase 1 / Phase 2 | 13 | University of Alabama at BirminghamOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT04483414 | 68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer | withdrawn | Phase 2 | 0 | Dana MathewsOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT04843319 | To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer(VERU-100) | terminated | Phase 1 / Phase 2 | 24 | Veru Inc.INDUSTRY | 1 | May 19, 2023 | clinicaltrials |
| NCT00583752 | Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21(APP21) | completed | Phase 2 | 50 | David M LubaroffOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT02058706 | LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer | completed | Phase 2 | 71 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT01278914 | Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Androgen Resistant Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | — | Oslo University HospitalOTHER | 1 | May 8, 2023 | clinicaltrials |
| NCT03429244 | PSMA-PET for Biopsy and Treatment Guidance in Primary Prostate Cancer | completed | Phase 2 | 36 | Indiana UniversityOTHER | 1 | May 8, 2023 | clinicaltrials |
| NCT00114985 | Prostate Immobilization Device Used During Radiation Treatments to Decrease Rectal Bleeding | completed | Phase 2 | 100 | Dana-Farber Cancer InstituteOTHER | 0 | May 3, 2023 | clinicaltrials |
| NCT03406858 | Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer | completed | Phase 2 | 15 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05841992 | Al18F-PSMA-617 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients | unknown | Phase 2 / Phase 3 | 100 | Peking Union Medical College HospitalOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT02881242 | Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer | active not recruiting | Phase 2 | 14 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT01751438 | Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery) | completed | Phase 2 | 180 | M.D. Anderson Cancer CenterOTHER | 2 | Apr 27, 2023 | clinicaltrials |
| NCT02159950 | Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 2 | 2 | Roswell Park Cancer InstituteOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT00268476 | Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy(STAMPEDE) | active not recruiting | Phase 2 / Phase 3 | 11,992 | Medical Research CouncilOTHER_GOV | 2 | Apr 18, 2023 | clinicaltrials |
| NCT04085991 | Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer(CROSSBOW) | terminated | Phase 2 | 11 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Apr 12, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Aug 22, 2023source: clinicaltrials